The presence of a human autoimmune phenotype (SAVI) and an ever-expanding number of pre-clinical and clinical studies support the potential for numerous STING agonist compounds in boosting anti-tumor immunity and enhancing the effects of existing immunotherapies. The gene discussed is STING1; the disease is STING-associated vasculopathy with onset in infancy.